Post-dilatation for Optimization of Drug-eluting Stents (DES) Deployment Assessed by Intravascular Ultrasound Multicenter Analysis (PODIUM)
Primary Purpose
Implant
Status
Unknown status
Phase
Phase 4
Locations
France
Study Type
Interventional
Intervention
post dilatation after stent deployment
stent deployment without post-dilatation
Sponsored by
About this trial
This is an interventional treatment trial for Implant focused on measuring Post-dilatation, noncompliant balloon, optimal stent deployment of drug-eluting stent, Intravascular ultrasound (IVUS), Optimal stent deployment defined by intravascular ultrasound analysis
Eligibility Criteria
Inclusion Criteria:
- Successful drug eluting stent implantation in a native coronary artery
Exclusion Criteria:
- Percutaneous coronary intervention (PCI) of Left main coronary artery;
- Myocardial infarction;
- Acute coronary syndrome;
- Emergency PCI;
- PCI for in-stent restenosis;
Sites / Locations
- Service de cardiologie interventionnelle - Hôpital LariboisièreRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Placebo Comparator
Active Comparator
Arm Label
classic strategy
post-dilatation strategy
Arm Description
after drug-eluting stent(DES) deployment perform of Intravascular ultrasound analysis without post-dilatation
After drug-eluting stent (DES) deployment IVUS analysis and systematic post-dilatation with noncompliant balloon 0.25mm larger than stent balloon. After post dilatation new IVUS analysis.
Outcomes
Primary Outcome Measures
Optimal stent deployment defined by IVUS analysis
The primary endpoint is optimum stent deployment. For defining the optimal stent deployment we use the IVUS criteria adopted in the MUSIC study: Complete apposition without underexpansion and with symmetric stent expansion. All patients(group A and B) will have IVUS analysis for defining optimal stent deployment
Secondary Outcome Measures
Complications of percutaneous coronary intervention (PCI)
Death,Myocardial infarction, coronary dissection, intracoronary thrombosis, target vessel revascularisation.
Full Information
NCT ID
NCT01103765
First Posted
April 13, 2010
Last Updated
June 14, 2011
Sponsor
Recherches et etudes en sciences sociales et sante, France
1. Study Identification
Unique Protocol Identification Number
NCT01103765
Brief Title
Post-dilatation for Optimization of Drug-eluting Stents (DES) Deployment Assessed by Intravascular Ultrasound Multicenter Analysis
Acronym
PODIUM
Official Title
A Prospective Randomized Multicenter Study of the Efficacy and Safety of Systematic Post -Dilatation With Noncompliant Balloon After Successful Drug-eluting Stent Implantation. IVUS Analysis.
Study Type
Interventional
2. Study Status
Record Verification Date
June 2011
Overall Recruitment Status
Unknown status
Study Start Date
April 2010 (undefined)
Primary Completion Date
November 2011 (Anticipated)
Study Completion Date
November 2011 (Anticipated)
3. Sponsor/Collaborators
Name of the Sponsor
Recherches et etudes en sciences sociales et sante, France
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Comparison with use of Intravascular Ultrasound (IVUS) analysis of two methods of percutaneous coronary interventions (PCI) with drug eluting stent:
After successful drug eluting stent implantation, patients were randomized into two groups: Group A had no further dilatation, and Group B had additional post-dilatation with a noncompliant balloon. The investigators performed IVUS analysis in groups A and B just before randomization and after post-dilatation in group B.
Detailed Description
Stent expansion of DES using current stent deliver systems is frequently suboptimal. Further more smaller minimal stent area (MSA) and stent underexpansion following deployment of DES are strong predictors of stent thrombosis and (TVR) target vessel revascularization. The investigators hypothesize than adjunctive postdilatation with noncompliant balloon can improve DES deployment.
After successful drug eluting stent implantation, patients will be randomized into two groups: Group A with no further dilatation, and Group B with additional post-dilatation with a noncompliant balloon. The investigators will performed IVUS analysis in groups A and B just before randomization and after post-dilatation in group B. Post dilatation will be performed with noncompliant balloon and with a nominal diameter 0.25mm larger than stent balloon.
The primary endpoint is optimum stent deployment. For defining the optimal stent deployment the investigators use the IVUS criteria adopted in the MUSIC study: Complete apposition without underexpansion and with symmetric stent expansion.
Patients are eligible after successful drug-eluting stent implantation in a native coronary artery. Patients with myocardial infarction or acute coronary syndrome will be excluded from the study.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Implant
Keywords
Post-dilatation, noncompliant balloon, optimal stent deployment of drug-eluting stent, Intravascular ultrasound (IVUS), Optimal stent deployment defined by intravascular ultrasound analysis
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
220 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
classic strategy
Arm Type
Placebo Comparator
Arm Description
after drug-eluting stent(DES) deployment perform of Intravascular ultrasound analysis without post-dilatation
Arm Title
post-dilatation strategy
Arm Type
Active Comparator
Arm Description
After drug-eluting stent (DES) deployment IVUS analysis and systematic post-dilatation with noncompliant balloon 0.25mm larger than stent balloon. After post dilatation new IVUS analysis.
Intervention Type
Procedure
Intervention Name(s)
post dilatation after stent deployment
Intervention Description
Post-dilatation with a noncompliant balloon larger 0.25mm than stent balloon.
Intervention Type
Procedure
Intervention Name(s)
stent deployment without post-dilatation
Intervention Description
stent deployment without systematic post dilatation
Primary Outcome Measure Information:
Title
Optimal stent deployment defined by IVUS analysis
Description
The primary endpoint is optimum stent deployment. For defining the optimal stent deployment we use the IVUS criteria adopted in the MUSIC study: Complete apposition without underexpansion and with symmetric stent expansion. All patients(group A and B) will have IVUS analysis for defining optimal stent deployment
Time Frame
at 18 months
Secondary Outcome Measure Information:
Title
Complications of percutaneous coronary intervention (PCI)
Description
Death,Myocardial infarction, coronary dissection, intracoronary thrombosis, target vessel revascularisation.
Time Frame
at day0, at day1, at the end of hospitalisation and year1
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Successful drug eluting stent implantation in a native coronary artery
Exclusion Criteria:
Percutaneous coronary intervention (PCI) of Left main coronary artery;
Myocardial infarction;
Acute coronary syndrome;
Emergency PCI;
PCI for in-stent restenosis;
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Georgios SIDERIS, MD
Phone
33(1) 01-49-95-82-04
Email
georgios.sideris@lrb.aphp.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Olivier VARENNE, MD
Phone
33(1) 58-41-16-53
Email
olivier.varenne@cch.aphp.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Georgios SIDERIS, MD
Organizational Affiliation
Assistance Publique - Hôpitaux de Paris
Official's Role
Principal Investigator
Facility Information:
Facility Name
Service de cardiologie interventionnelle - Hôpital Lariboisière
City
Paris
ZIP/Postal Code
75010
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Georgios SIDERIS, MD
Phone
33(1) 49-95-82-04
Email
georgios.sideris@lrb.aphp.fr
First Name & Middle Initial & Last Name & Degree
Olivier VARENNE, MD
Phone
33(1) 58-41-16-53
Email
olivier.varenne@cch.aphp.fr
First Name & Middle Initial & Last Name & Degree
Georgios SIDERIS, MD
12. IPD Sharing Statement
Learn more about this trial
Post-dilatation for Optimization of Drug-eluting Stents (DES) Deployment Assessed by Intravascular Ultrasound Multicenter Analysis
We'll reach out to this number within 24 hrs